Oregovomab

DB04964

biotech investigational

Deskripsi

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Oregovomab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Oregovomab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Oregovomab.
Estrone Estrone may increase the thrombogenic activities of Oregovomab.
Estradiol Estradiol may increase the thrombogenic activities of Oregovomab.
Dienestrol Dienestrol may increase the thrombogenic activities of Oregovomab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Oregovomab.
Mestranol Mestranol may increase the thrombogenic activities of Oregovomab.
Estriol Estriol may increase the thrombogenic activities of Oregovomab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Oregovomab.
Quinestrol Quinestrol may increase the thrombogenic activities of Oregovomab.
Hexestrol Hexestrol may increase the thrombogenic activities of Oregovomab.
Tibolone Tibolone may increase the thrombogenic activities of Oregovomab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Oregovomab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Oregovomab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Oregovomab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Oregovomab.
Zeranol Zeranol may increase the thrombogenic activities of Oregovomab.
Equol Equol may increase the thrombogenic activities of Oregovomab.
Promestriene Promestriene may increase the thrombogenic activities of Oregovomab.
Methallenestril Methallenestril may increase the thrombogenic activities of Oregovomab.
Epimestrol Epimestrol may increase the thrombogenic activities of Oregovomab.
Moxestrol Moxestrol may increase the thrombogenic activities of Oregovomab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Oregovomab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Oregovomab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Oregovomab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Oregovomab.
Biochanin A Biochanin A may increase the thrombogenic activities of Oregovomab.
Formononetin Formononetin may increase the thrombogenic activities of Oregovomab.
Estetrol Estetrol may increase the thrombogenic activities of Oregovomab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Oregovomab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Oregovomab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Oregovomab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Oregovomab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Oregovomab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oregovomab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Oregovomab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Oregovomab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Oregovomab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Oregovomab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Oregovomab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Oregovomab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Oregovomab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oregovomab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Oregovomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Oregovomab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Oregovomab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oregovomab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Oregovomab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Oregovomab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Oregovomab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oregovomab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Oregovomab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Oregovomab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Oregovomab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Oregovomab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Oregovomab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Oregovomab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Oregovomab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Oregovomab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Oregovomab.
IGN311 The risk or severity of adverse effects can be increased when Oregovomab is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Oregovomab is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Oregovomab is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Oregovomab is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Oregovomab is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Oregovomab is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Oregovomab is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Oregovomab is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Oregovomab is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Oregovomab is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Oregovomab is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Oregovomab is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Oregovomab is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Oregovomab is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Oregovomab is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Oregovomab is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Oregovomab is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Oregovomab is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Oregovomab is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Oregovomab is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Oregovomab is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Oregovomab is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Oregovomab is combined with Canakinumab.

Target Protein

Mucin-16 MUC16

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15268682
    Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65.
  • PMID: 15297171
    Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004 Aug;94(2):340-51.
  • PMID: 16343178
    Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34.
  • PMID: 17073521
    Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • OvaRex

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul